Central Pacific Bank Trust Division Takes $178,000 Position in LivaNova PLC (NASDAQ:LIVN)

Central Pacific Bank Trust Division purchased a new stake in LivaNova PLC (NASDAQ:LIVN) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund purchased 3,397 shares of the company’s stock, valued at approximately $178,000.

Several other institutional investors and hedge funds also recently made changes to their positions in LIVN. Point72 Asset Management L.P. boosted its stake in LivaNova by 204.3% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,285,636 shares of the company’s stock worth $70,479,000 after purchasing an additional 863,157 shares during the period. First Light Asset Management LLC boosted its stake in LivaNova by 591.1% in the 2nd quarter. First Light Asset Management LLC now owns 710,390 shares of the company’s stock worth $38,944,000 after purchasing an additional 607,598 shares during the period. Great Lakes Advisors LLC acquired a new position in LivaNova in the 2nd quarter worth $16,614,000. Mesirow Institutional Investment Management Inc. acquired a new position in LivaNova in the 1st quarter worth $13,816,000. Finally, Driehaus Capital Management LLC boosted its stake in LivaNova by 64.7% in the 2nd quarter. Driehaus Capital Management LLC now owns 544,042 shares of the company’s stock worth $29,824,000 after purchasing an additional 213,749 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts recently weighed in on LIVN shares. Robert W. Baird raised shares of LivaNova from a “neutral” rating to an “outperform” rating and upped their target price for the stock from $55.00 to $66.00 in a research note on Tuesday, September 17th. Needham & Company LLC increased their price objective on shares of LivaNova from $72.00 to $75.00 and gave the stock a “buy” rating in a research note on Wednesday, July 31st. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 17th. The Goldman Sachs Group started coverage on shares of LivaNova in a research note on Friday. They set a “buy” rating and a $65.00 price objective for the company. Finally, Stifel Nicolaus increased their price objective on shares of LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. One equities research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $69.83.

LivaNova Stock Up 1.2 %

Shares of LIVN stock opened at $53.83 on Friday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 2.94 and a current ratio of 3.45. The firm’s 50-day moving average is $48.63 and its 200-day moving average is $53.39. The stock has a market cap of $2.92 billion, a price-to-earnings ratio of -89.72 and a beta of 1.00. LivaNova PLC has a 52-week low of $42.75 and a 52-week high of $64.47.

LivaNova (NASDAQ:LIVN) last issued its earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.66 by $0.15. The company had revenue of $318.60 million for the quarter, compared to analysts’ expectations of $305.05 million. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. Sell-side analysts predict that LivaNova PLC will post 2.58 EPS for the current year.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.